Article ID Journal Published Year Pages File Type
8786223 Clinical Oncology 2018 10 Pages PDF
Abstract
Six UK studies investigating stereotactic ablative radiotherapy (SABR) are currently open. Many of these involve the treatment of oligometastatic disease at different locations in the body. Members of all the trial management groups collaborated to generate a consensus document on appropriate organ at risk dose constraints. Values from existing but older reviews were updated using data from current studies. It is hoped that this unified approach will facilitate standardised implementation of SABR across the UK and will allow meaningful toxicity comparisons between SABR studies and internationally.
Related Topics
Health Sciences Medicine and Dentistry Oncology
Authors
, , , , , , , , , , , , , , , , , ,